BIAFHealthcare · Diagnostics & Research

BIAF Stock Forecast: bioAffinity Technologies, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026

$5.82

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$216,046.00

Ticker Nerd rank

16 / 100

Median analyst target

—

Analysts covering

Revenue$1.4M−27.1% y/y

Operating income−$3.6M

Net income−$3.6M

Free cash flow−$3.2M

Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown

Ticker Nerd rank

BIAF stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores bioAffinity Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Accruals

Growth

Momentum

Revisions

Value

Quality

Issuance

Size (98): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIAF stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIAF, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts

0 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
1 Apr 2025	Maxim Group	Downgrade	Hold	—
23 July 2024	Maxim Group	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIAF appears on the weeks it earns a place.

Estimates

BIAF analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

bioAffinity Technologies, Inc. (BIAF) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: 0.5×
Price / book: 10.8×
EV / EBITDA: −4.0×

Growth & margins

Revenue growth (YoY): 19.0%
Earnings growth (YoY): −27.1%
Gross margin: 31.3%
Operating margin: −220.8%
Net margin: −257.3%

Returns & dividend

Return on equity: −1860.2%
Return on assets: −125.1%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

bioAffinity Technologies, Inc. (BIAF) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

bioAffinity Technologies, Inc. has a market value of $216K and an enterprise value of $47.6M.
Revenue in the twelve months to 31 Mar 2026: $5.6M. The latest quarter grew 19.0% year on year.
Net income over the same four quarters: −$15.9M, a −283.3% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$10.9M, after $15K of capital spending.
Shares outstanding: 540,115.
Trailing P/E: −0.0×; forward P/E: −10.0× — the forward figure prices analyst consensus estimates, not reported earnings.
bioAffinity Technologies, Inc. employs 57 people — $98K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

BIAF vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research

Company	Market cap	TKN rank
BIAFbioAffinity Technologies, Inc.	$216,046.00	16
ISPCiSpecimen, Inc.	$4.3M	23
NDRAENDRA Life Sciences, Inc.	$6.7M	37
XWELXWELL, Inc.	$8.8M	39
MBAICheck-Cap Ltd.	$10.9M	7
ADVBAdvanced Biomed, Inc.	$13.4M	16
PRPOPrecipio, Inc.	$53.3M	52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own bioAffinity Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIAF news & analysis

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Business Wire · 20 Aug 2026neutral

bioAffinity Technologies announced it will implement a 1-for-15 reverse split of its common stock, effective at the opening of trading on Nasdaq on August 24, 2026. The announcement was made via Business Wire.

Why it matters — A reverse stock split reduces the number of outstanding shares and proportionally raises the per-share price, which can affect how BIAF shares trade and are valued for Nasdaq compliance.

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

Business Wire · 18 Aug 2026positive

bioAffinity Technologies has entered a nationwide federal healthcare distribution agreement with AvMEDICAL to expand the sales reach of CyPath® Lung and its access to government healthcare systems.

Why it matters — A BIAF watcher would care because this agreement broadens distribution of CyPath Lung into federal and government healthcare channels, potentially widening the product's market access.

WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

PRNewsWire · 14 Aug 2026neutral

WallachBeth Capital announced that bioAffinity Technologies has closed its previously announced private placement, priced at-the-market under Nasdaq rules, involving the purchase and sale of pre-funded warrants for an aggregate of 8,462,027 shares of common stock for $4 million.

Why it matters — This closing provides bioAffinity Technologies with additional capital through the issuance of pre-funded warrants, a development relevant to BIAF investors following the company's financing activity.

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Business Wire · 14 Aug 2026neutral

bioAffinity Technologies announced the closing of a $4 million private placement offering priced at-the-market under Nasdaq rules. The company's announcement of the offering's closing was made via Business Wire from San Antonio.

Why it matters — A BIAF watcher would care because the completed private placement provides the company with additional capital, potentially supporting its ongoing operations and business activities.

WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

PRNewsWire · 13 Aug 2026neutral

bioAffinity Technologies announced that it entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof) along with two warrants covering up to 16,924,054 additional shares in a $4 million private placement priced at-the-market under Nasdaq rules. WallachBeth Capital announced the pricing.

Why it matters — BIAF watchers would care because the company's private placement issuance of shares and warrants represents a new capital raise that affects the company's funding and share structure.

FAQ

Frequently asked questions about BIAF stock

Is BIAF stock a buy right now?

Of the 1 analysts covering bioAffinity Technologies, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks bioAffinity Technologies, Inc. 16 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIAF?

As at 22 Aug 2026, bioAffinity Technologies, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the BIAF stock forecast for 2030?

No analyst covering bioAffinity Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIAF are extrapolating price history, which says nothing about the business.

What does bioAffinity Technologies, Inc. do?

BioAffinity Technologies Inc. is a biotechnology company specializing in noninvasive diagnostics and targeted cancer therapeutics for early-stage lung cancer and other lung diseases.

What is the latest news on BIAF?

The most recent item we track (Business Wire, 20 Aug 2026): "bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026". bioAffinity Technologies announced it will implement a 1-for-15 reverse split of its common stock, effective at the opening of trading on Nasdaq on August 24, 2026. The announcement was made via Business Wire.

Company

About bioAffinity Technologies, Inc.

BioAffinity Technologies Inc. is a biotechnology company specializing in noninvasive diagnostics and targeted cancer therapeutics for early-stage lung cancer and other lung diseases. Its flagship product, CyPath Lung, employs flow cytometry technology and automated AI analysis to examine sputum samples, identifying cell populations indicative of malignancy, including cancer cells shed from lung tumors. This enables early detection in high-risk patients, potentially reducing the need for invasive biopsies. The company operates through Diagnostic Research and Development and Laboratory Services segments, with its Precision Pathology Laboratory Services providing anatomic and clinical pathology support. BioAffinity Technologies Inc. also advances its platform technology for applications in asthma and COPD, such as matching patients to biologic therapies by detecting antibody drug receptors in sputum. Additionally, through its subsidiary OncoSelect Therapeutics, it researches porphyrin-based therapies that selectively target and kill cancer cells. Founded in 2014 and headquartered in San Antonio, Texas, BioAffinity Technologies Inc. plays a key role in the in vitro diagnostics sector of healthcare, addressing critical needs in oncology and respiratory medicine.

CEO Ms. Maria Zannes J.D. · 57 employees · United States · https://bioaffinitytech.com